Unique ID issued by UMIN | UMIN000057795 |
---|---|
Receipt number | R000065994 |
Scientific Title | Single-blind randomized controlled trial of the effect of preoperative expiratory muscle training on postoperative swallowing function in patients with esophageal cancer: A phase II trial |
Date of disclosure of the study information | 2025/06/30 |
Last modified on | 2025/05/02 05:22:33 |
Single-blind randomized controlled trial of the effect of preoperative expiratory muscle training on swallowing function in patients with esophageal cancer: A phase II trial
Preoperative expiratory muscle training and swallowing function in esophageal cancer patients
Single-blind randomized controlled trial of the effect of preoperative expiratory muscle training on postoperative swallowing function in patients with esophageal cancer: A phase II trial
Preoperative expiratory muscle training and postoperative swallowing function in esophageal cancer patients
Japan |
Patients with thoracic esophageal cancer
Gastrointestinal surgery | Rehabilitation medicine | Adult |
Malignancy
NO
This phase II single-blind randomized controlled trial aims to evaluate the efficacy of expiratory muscle training during neoadjuvant therapy on postoperative swallowing function in patients with thoracic esophageal cancer undergoing esophagectomy.
Others
Postoperative incidence of aspiration will be compared between the two groups to determine the effect size, which will inform the design of a future multicenter collaborative trial.
Confirmatory
Explanatory
Phase II
Penetration-Aspiration Scale (PAS) score assessed during video-fluoroscopic swallowing study
Repeated Saliva Swallowing Test, Functional Oral Intake Scale, Tongue pressure
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Placebo
YES
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Educational,Counseling,Training
Device,equipment |
Sham-Expiratory muscle training
Expiratory muscle training
40 | years-old | <= |
Not applicable |
Male and Female
Eligible participants must meet all of the following criteria and provide written informed consent:
Patients aged 40 years or older with esophageal cancer scheduled to undergo esophagectomy and reconstruction following neoadjuvant therapy at Kindai University Hospital.
Patients receiving initial treatment for esophageal cancer.
Patients without severe comorbidities involving major organs (e.g., bone marrow, heart, liver, kidneys).
Patients who have received a full explanation of the study and have provided written informed consent.
Patients who are able to walk independently.
Participants meeting any of the following criteria will be excluded from the study:
Patients scheduled to undergo staged esophageal reconstruction or total laryngectomy.
Patients with contraindications to the use of the expiratory muscle training device (EX-1 Medic), including:
Patients with asthma who frequently experience exacerbations
Patients with tympanic membrane perforation or other ear injuries
Patients with markedly elevated left ventricular end-diastolic volume or pressure
Patients who have experienced worsening signs or symptoms of heart failure following respiratory muscle training, or those diagnosed by a physician as being at high risk of such deterioration
Patients with a history of costochondritis or those diagnosed as likely to have it
Patients with active infections or other severe complications* who are judged by the attending physician to be at risk of adverse events associated with expiratory muscle training (EMT), such as increased dyspnea due to respiratory muscle fatigue, decreased consciousness due to hyperventilation, or syncope due to abrupt changes in blood pressure or hemodynamics caused by intrathoracic pressure fluctuations.
Patients with disorientation or psychiatric disorders that would preclude appropriate participation in the study.
Patients deemed by the investigator or sub-investigator to be unsuitable for EMT due to a high risk of pneumothorax from extensive emphysematous lesions or giant bullae, leading to increased physical burden or potential harm from participation in the study.
*Severe complications include severe pneumonia, cardiac disease, hepatic disease, renal disease; patients with cardiac events (e.g., unstable angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery) within the past month; cerebrovascular disease within the past 6 months; or the presence of extensive emphysematous changes or giant bullae.
40
1st name | Yuji |
Middle name | |
Last name | Higashimoto |
Faculty of Medicine, Kindai university
Department of Rehabilitation Medicine
589-5811
377-2, Ohno-Higashi Osakasayama-City, JAPAN
072-366-0221
yhigashi@med.kindai.ac.jp
1st name | Hiroki |
Middle name | |
Last name | Mizusawa |
Kindai university hospital
Department of rehabilitation medicine
589-5811
377-2, Ohno-Higashi Osakasayama-City, JAPAN
072-366-0221
hiroki-mizusawa@med.kindai.ac.jp
Kindai university hospital
Grant-In-Aid for Scientific Research from the Ministry of Education, Science and Culture of the Japanese Government
Other
he Committee for Ethics of the Kindai University School of Medicine
377-2, Ohno-Higashi Osakasayama-City, JAPAN
072-366-0221
zizen@med.kindai.ac.jp
NO
2025 | Year | 06 | Month | 30 | Day |
Unpublished
Preinitiation
2025 | Year | 04 | Month | 01 | Day |
2025 | Year | 04 | Month | 09 | Day |
2025 | Year | 05 | Month | 25 | Day |
2029 | Year | 05 | Month | 31 | Day |
2025 | Year | 05 | Month | 08 | Day |
2025 | Year | 05 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065994